155 related articles for article (PubMed ID: 38214355)
1. Development and Evaluation of a Novel Hyaluronic Acid and Chitosan-modified Phytosome for Co-delivery of Oxymatrine and Glycyrrhizin for Combination Therapy.
Chen X; Yu S; Wang P; Zhao X; Sang G
Recent Pat Anticancer Drug Discov; 2024; 19(2):154-164. PubMed ID: 38214355
[TBL] [Abstract][Full Text] [Related]
2. Glycyrrhizin conjugated chitosan nanoparticles for hepatocyte-targeted delivery of lamivudine.
Mishra D; Jain N; Rajoriya V; Jain AK
J Pharm Pharmacol; 2014 Aug; 66(8):1082-93. PubMed ID: 24641311
[TBL] [Abstract][Full Text] [Related]
3. Glycyrrhizin surface-modified chitosan nanoparticles for hepatocyte-targeted delivery.
Lin A; Liu Y; Huang Y; Sun J; Wu Z; Zhang X; Ping Q
Int J Pharm; 2008 Jul; 359(1-2):247-53. PubMed ID: 18457928
[TBL] [Abstract][Full Text] [Related]
4. Phytosome-hyaluronic acid systems for ocular delivery of L-carnosine.
Abdelkader H; Longman MR; Alany RG; Pierscionek B
Int J Nanomedicine; 2016; 11():2815-27. PubMed ID: 27366062
[TBL] [Abstract][Full Text] [Related]
5. Preparation and evaluation of N-caproyl chitosan nanoparticles surface modified with glycyrrhizin for hepatocyte targeting.
Lin A; Chen J; Liu Y; Deng S; Wu Z; Huang Y; Ping Q
Drug Dev Ind Pharm; 2009 Nov; 35(11):1348-55. PubMed ID: 19832635
[TBL] [Abstract][Full Text] [Related]
6. The investigation on sialic acid-modified pectin nanoparticles loaded with oxymatrine for orally targeting and inhibiting the of ulcerative colitis.
Zhao C; Yang X; Fan M; Tian L; Sun T; Sun C; Jiang T
Colloids Surf B Biointerfaces; 2024 Apr; 236():113809. PubMed ID: 38447446
[TBL] [Abstract][Full Text] [Related]
7. Chitosan-hyaluronic acid nanoparticles loaded with heparin for the treatment of asthma.
Oyarzun-Ampuero FA; Brea J; Loza MI; Torres D; Alonso MJ
Int J Pharm; 2009 Nov; 381(2):122-9. PubMed ID: 19467809
[TBL] [Abstract][Full Text] [Related]
8. Hyaluronic acid-oleylamine and chitosan-oleic acid conjugate-based hybrid nanoparticle delivery via. dissolving microneedles for enhanced treatment efficacy in localized breast cancer.
Jha A; Kumar M; Goswami P; Manjit M; Bharti K; Koch B; Mishra B
Biomater Adv; 2024 Jun; 160():213865. PubMed ID: 38643693
[TBL] [Abstract][Full Text] [Related]
9. Development of chitosan nanoparticles coated with hyaluronic acid for topical ocular delivery of dexamethasone.
Kalam MA
Int J Biol Macromol; 2016 Aug; 89():127-36. PubMed ID: 27126165
[TBL] [Abstract][Full Text] [Related]
10. Raloxifene-encapsulated hyaluronic acid-decorated chitosan nanoparticles selectively induce apoptosis in lung cancer cells.
Almutairi FM; Abd-Rabou AA; Mohamed MS
Bioorg Med Chem; 2019 Apr; 27(8):1629-1638. PubMed ID: 30879864
[TBL] [Abstract][Full Text] [Related]
11. Glycyrrhizin-modified O-carboxymethyl chitosan nanoparticles as drug vehicles targeting hepatocellular carcinoma.
Shi L; Tang C; Yin C
Biomaterials; 2012 Oct; 33(30):7594-604. PubMed ID: 22796165
[TBL] [Abstract][Full Text] [Related]
12. Hyaluronic acid-coated chitosan nanoparticles as targeted-carrier of tamoxifen against MCF7 and TMX-resistant MCF7 cells.
Nokhodi F; Nekoei M; Goodarzi MT
J Mater Sci Mater Med; 2022 Feb; 33(2):24. PubMed ID: 35157166
[TBL] [Abstract][Full Text] [Related]
13. Intermolecular interactions between salmon calcitonin, hyaluronate, and chitosan and their impact on the process of formation and properties of peptide-loaded nanoparticles.
Umerska A; Corrigan OI; Tajber L
Int J Pharm; 2014 Dec; 477(1-2):102-12. PubMed ID: 25447822
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: development, characterization, and evaluation.
Wadhwa S; Paliwal R; Paliwal SR; Vyas SP
J Drug Target; 2010 May; 18(4):292-302. PubMed ID: 19943753
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy.
Gao Z; Li Z; Yan J; Wang P
Drug Des Devel Ther; 2017; 11():2595-2604. PubMed ID: 28919710
[TBL] [Abstract][Full Text] [Related]
16. Hyaluronic acid-modified betamethasone encapsulated polymeric nanoparticles: fabrication, characterisation, in vitro release kinetics, and dermal targeting.
Pandey M; Choudhury H; Gunasegaran TAP; Nathan SS; Md S; Gorain B; Tripathy M; Hussain Z
Drug Deliv Transl Res; 2019 Apr; 9(2):520-533. PubMed ID: 29488170
[TBL] [Abstract][Full Text] [Related]
17. Effect of preparation parameters on ultra low molecular weight chitosan/hyaluronic acid nanoparticles.
Nazeri N; Avadi MR; Faramarzi MA; Safarian S; Tavoosidana G; Khoshayand MR; Amani A
Int J Biol Macromol; 2013 Nov; 62():642-6. PubMed ID: 24099942
[TBL] [Abstract][Full Text] [Related]
18. CD44-specific nanoparticles for redox-triggered reactive oxygen species production and doxorubicin release.
Lin CW; Lu KY; Wang SY; Sung HW; Mi FL
Acta Biomater; 2016 Apr; 35():280-92. PubMed ID: 26853764
[TBL] [Abstract][Full Text] [Related]
19. Aptamer-modified chitosan-capped mesoporous silica nanoparticles for co-delivery of cytarabine and daunorubicin in leukemia.
Heydari SR; Ghahremani MH; Atyabi F; Bafkary R; Jaafari MR; Dinarvand R
Int J Pharm; 2023 Nov; 646():123495. PubMed ID: 37806507
[TBL] [Abstract][Full Text] [Related]
20. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment.
Bagre AP; Jain K; Jain NK
Int J Pharm; 2013 Nov; 456(1):31-40. PubMed ID: 23994363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
